CliffBio
small molecule

IBTROZI

TALETRECTINIB ADIPATE

Loss of exclusivityJune 2033latest FDA-listed patent expiry
CompanyNuvation Bio →View the full company profile on CliffBio

Drug detail

Brand nameIBTROZI
Active ingredientTALETRECTINIB ADIPATE
StrengthEQ 200MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2025
Marketing statusRX

Listed patents

PatentExpiresType
9751887June 2033substance, product
9187489June 2033substance, product

Regulatory exclusivity

CodeExpires
ODE-544June 2032
NCEJune 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

IBTROZI patent cliff — loss of exclusivity June 2033 | CliffBio